Cytiva expands Massachusetts biomanufacturing site

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Belchonock)
(Image: Getty/Belchonock)

Related tags: Cytiva, Massachusetts, Biotechs

The facility has been expanded to cater to the growing number of small- to mid-size biotechs looking to contract manufacture.

Cytiva announced that it had completed the renovation and expansion of its ‘Fast Trak’ contract biomanufacturing and process development site in Marlborough, US.

After the expansion, the facility now covers 60,00-square-feet of space and has the bioprocessing capacity to move from 10L to 2,000L scale. The services will be utilized to progress drug candidates through preclinical work onto Phase II.

Olivier Loeillot, SVP of BioProcess at Cytiva, explained that the facility will primarily serve small- to mid-size companies aiming to expedite processes, with biotech companies working to outsource manufacture to access expertise and capacity.

The upgraded site will feature an automated platform that is able to gather data to improve efficiency through the upstream and downstream process, the company stated.

LockeDrive 2
The expanded facility. Image: Cytiva

In addition to providing the contract services for biomanufacturing, the company outlined that any company using its Fast Trak facility would be able to place staff members in the plant, with Cytiva’s scientists providing training on the manufacturing process.

Cytiva was created earlier this year​, after Danaher acquired GE Life Sciences for $21bn (€18.6bn) and the resulting business unit took on the new moniker.

Since that time, the company has provided an update on its services for cell therapies​, by offering a shipping system specifically designed for this kind of treatment, as it pivots to the growing pipeline​ of cell and gene therapies.

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us


View more